Current developments in gastric cancer: from molecular profiling to treatment strategy

被引：212

作者：

Alsina, Maria ^{[1
,2
,3
]}

Arrazubi, Virginia ^{[2
,3
]}

Diez, Marc ^{[1
,4
]}

Tabernero, Josep ^{[1
,4
]}

机构：

[1] Vall Hebron Inst Oncol VHIO, Gastrointestinal & Endocrinol Grp, Barcelona, Spain

[2] Hosp Univ Navarra HUN, Med Oncol Dept, Pamplona, Spain

[3] Inst Invest Sanitaria Navarra IdiSNA, Oncobiona Grp, Pamplona, Spain

[4] Hosp Univ Vall Hebron HUVH, Med Oncol Dept, Barcelona, Spain

来源：

NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY | 2023年 / 20卷 / 03期

关键词：

RANDOMIZED PHASE-III; PLUS CHEMOTHERAPY CHEMO; DERUXTECAN T-DXD; GASTROESOPHAGEAL JUNCTION; DOUBLE-BLIND; OPEN-LABEL; 1ST-LINE THERAPY; PERIOPERATIVE TRASTUZUMAB; ADENOCARCINOMA; CAPECITABINE;

D O I：

10.1038/s41575-022-00703-w

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

Gastric cancer and gastro-oesophageal junction cancer represent a global health-care challenge. Despite the efficacy of improved chemotherapy and surgical options, these patients still have a poor prognosis. In advanced disease, only trastuzumab and some immune checkpoint inhibitors, such as nivolumab and pembrolizumab in addition to chemotherapy, have demonstrated consistent and reliable efficacy in patients with HER2-positive and PDL1-positive tumours, respectively. In this Review, we discuss the intrinsic characteristics of gastric and gastro-oesophageal cancer from the molecular and clinical perspectives and provide a comprehensive review of previously reported and ongoing phase II and III clinical trials with targeted agents and immunotherapy in advanced and localized settings. Finally, we suggest alternative strategies to help overcome current challenges in precision medicine and to improve outcomes for these patients. Gastric and gastro-oesophageal cancer is a leading cause of cancer-related death worldwide with a poor prognosis. This Review provides a comprehensive overview of current treatment strategies set on a molecular basis, and discusses future therapeutic avenues.

引用

页码：155 / 170

页数：16

共 122 条

[1] Perioperative FLOT plus ramucirumab versus FLOT alone for resectable esophagogastric adenocarcinoma- Updated results and subgroup analyses of the randomized phase II/III trial RAMSES/FLOT7 of the German AIO and Italian GOIM [J].

Al-Batran, S-E. ;

Hofheinz, R. D. ;

Schmalenberg, H. ;

Strumberg, D. ;

Goekkurt, E. ;

Angermeier, S. ;

Zander, T. ;

Potenberg, J. ;

Kopp, H-G. ;

Pink, D. ;

Siegler, G. M. ;

Schenk, M. ;

De Vita, F. ;

Maiello, E. ;

Gaiser, T. ;

Sookthai, D. ;

Bankstahl, U. S. ;

Pauligk, C. ;

Goetze, T. O. ;

Homann, N. .

ANNALS OF ONCOLOGY, 2020, 31 :S901-S901

[2] Final results and subgroup analysis of the PETRARCA randomized phase II AIO trial: Perioperative trastuzumab and pertuzumab in combination with FLOT versus FLOT alone for HER2 positive resectable esophagogastric adenocarcinoma [J].

Al-Batran, S-E. ;

Haag, G. M. ;

Ettrich, T. J. ;

Borchert, K. ;

Kretzschmar, A. ;

Teschendorf, C. ;

Siegler, G. M. ;

Ebert, M. ;

Goekkurt, E. ;

Welslau, M. K. ;

Mahlberg, R. J. C. ;

Homann, N. ;

Pink, D. ;

Bechstein, W. O. ;

Reichardt, P. ;

Gaiser, T. ;

Sookthai, D. ;

Pauligk, C. ;

Goetze, T. O. ;

Hofheinz, R. D. .

ANNALS OF ONCOLOGY, 2020, 31 :S899-S899

[3] Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin:: A study of the arbeitsgemeinschaft internistische onkologie [J].

Al-Batran, Salah-Eddin ;

Hartmann, Joerg Thomas ;

Probst, Stephan ;

Schmalenberg, Harald ;

Hollerbach, Stephan ;

Hofheinz, Ralf ;

Rethwisch, Volker ;

Seipelt, Gernot ;

Homann, Nils ;

Wilhelm, Gerhard ;

Schuch, Gunter ;

Stoehlmacher, Jan ;

Derigs, Hans Guenter ;

Hegewisch-Becker, Susanna ;

Grossmann, Johannes ;

Pauligk, Claudia ;

Atmaca, Akin ;

Bokemeyer, Carsten ;

Knuth, Alexander ;

Jaeger, Elke .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (09) :1435-1442

[4] Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial [J].

Al-Batran, Salah-Eddin ;

Homann, Nils ;

Pauligk, Claudia ;

Goetze, Thorsten O. ;

Meiler, Johannes ;

Kasper, Stefan ;

Kopp, Hans-Georg ;

Mayer, Frank ;

Haag, Georg Martin ;

Luley, Kim ;

Lindig, Udo ;

Schmiegel, Wolff ;

Pohl, Michael ;

Stoehlmacher, Jan ;

Folprecht, Gunnar ;

Probst, Stephan ;

Prasnikar, Nicole ;

Fischbach, Wolfgang ;

Mahlberg, Rolf ;

Trojan, Joerg ;

Koenigsmann, Michael ;

Martens, Uwe M. ;

Thuss-Patience, Peter ;

Egger, Matthias ;

Block, Andreas ;

Heinemann, Volker ;

Illerhaus, Gerald ;

Moehler, Markus ;

Schenk, Michael ;

Kullmann, Frank ;

Behringer, Dirk M. ;

Heike, Michael ;

Pink, Daniel ;

Teschendorf, Christian ;

Loehr, Carmen ;

Bernhard, Helga ;

Schuch, Gunter ;

Rethwisch, Volker ;

von Weikersthal, Ludwig Fischer ;

Hartmann, Joerg T. ;

Kneba, Michael ;

Daum, Severin ;

Schulmann, Karsten ;

Weniger, Joerg ;

Belle, Sebastian ;

Gaiser, Timo ;

Oduncu, Fuat S. ;

Guentner, Martina ;

Hozaeel, Wael ;

Reichart, Alexander .

LANCET, 2019, 393 (10184) :1948-1957

[5] Phase II trial of perioperative chemotherapy plus avelumab in locally advanced gastroesophageal adenocarcinoma: Preliminary results. [J].

Alcindor, Thierry ;

Opu, Touhid ;

Elkrief, Arielle ;

Khosrow-Khavar, Farzin ;

Mueller, Carmen L. ;

Cools-Lartigue, Jonathan ;

Hickeson, Marc ;

Artho, Giovanni ;

Evaristo, Gertruda ;

Marcus, Victoria ;

Camilleri-Broet, Sophie ;

Fiset, Pierre-Olivier ;

Spatz, Alan ;

Koulouris, Zoe ;

Ferri, Lorenzo .

JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)

[6] Signatures of mutational processes in human cancer [J].

Alexandrov, Ludmil B. ;

Nik-Zainal, Serena ;

Wedge, David C. ;

Aparicio, Samuel A. J. R. ;

Behjati, Sam ;

Biankin, Andrew V. ;

Bignell, Graham R. ;

Bolli, Niccolo ;

Borg, Ake ;

Borresen-Dale, Anne-Lise ;

Boyault, Sandrine ;

Burkhardt, Birgit ;

Butler, Adam P. ;

Caldas, Carlos ;

Davies, Helen R. ;

Desmedt, Christine ;

Eils, Roland ;

Eyfjord, Jorunn Erla ;

Foekens, John A. ;

Greaves, Mel ;

Hosoda, Fumie ;

Hutter, Barbara ;

Ilicic, Tomislav ;

Imbeaud, Sandrine ;

Imielinsk, Marcin ;

Jaeger, Natalie ;

Jones, David T. W. ;

Jones, David ;

Knappskog, Stian ;

Kool, Marcel ;

Lakhani, Sunil R. ;

Lopez-Otin, Carlos ;

Martin, Sancha ;

Munshi, Nikhil C. ;

Nakamura, Hiromi ;

Northcott, Paul A. ;

Pajic, Marina ;

Papaemmanuil, Elli ;

Paradiso, Angelo ;

Pearson, John V. ;

Puente, Xose S. ;

Raine, Keiran ;

Ramakrishna, Manasa ;

Richardson, Andrea L. ;

Richter, Julia ;

Rosenstiel, Philip ;

Schlesner, Matthias ;

Schumacher, Ton N. ;

Span, Paul N. ;

Teague, Jon W. .

NATURE, 2013, 500 (7463) :415-+

[7] Intratumoral heterogeneity in gastric cancer: a new challenge to face [J].

Alsina, M. ;

Gullo, I. ;

Carneiro, F. .

ANNALS OF ONCOLOGY, 2017, 28 (05) :912-913

[8] MONEO: A phase II study of avelumab (Av) plus FLOT in the peri-operative treatment for patients (pts) with resectable gastric or gastroesophageal junction cancer (GC). [J].

Alsina, Maria ;

Ponz-Sarvise, Mariano ;

Garcia, Dario Lopez ;

Gonzalez, Marta ;

De Andrea, Carlos E. ;

Gros, Alena ;

Vivancos, Ana ;

Jimenez-Fonseca, Paula ;

Garcia, Marc Diez ;

Arrazubi, Virginia ;

Sanz-Garcia, Enrique ;

de Castro, Eva Martinez ;

Guardeno, Raquel ;

Calvo, Mariona ;

Buges, Cristina ;

Longo, Federico ;

Tabernero, Josep ;

Villacampa, Guillermo ;

Munoz, Susana ;

Melero, Ignacio .

JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)

[9] Emerging biological drugs for the treatment of gastroesophageal adenocarcinoma [J].

Alsina, Maria ;

Diez, Marc ;

Tabernero, Josep .

EXPERT OPINION ON EMERGING DRUGS, 2021, 26 (04) :385-400

[10]

American Cancer Society, 2021, Cancer Facts & Figures 2021

← 1 2 3 4 5 6 7 8 9 10 →